Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity

Brain Research

Volumn 813, Issue 2, 1998, Pages 323-328

  Strangman, Nicole M ^b   Patrick, Saundra L ^b   Hohmann, Andrea G ^a   Tsou, Kang ^a   Walker, J Michael ^a  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Cannabinoid; Formalin; Hyperalgesia; Pain; SRI41716A

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; HYPERALGESIA; NERVE STIMULATION; NEUROMODULATION; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT;

ACUTE DISEASE; ANALGESICS; ANIMALS; CANNABINOIDS; DISINFECTANTS; FORMALDEHYDE; HYPERALGESIA; MORPHOLINES; NAPHTHALENES; PAIN THRESHOLD; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032495194     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01031-2     Document Type: Article

References (33)

1. Abbott F.V., Franklin K.B.J., Westbrook R.F. The formalin test: scoring properties of the first and second phases of the pain response in rats. Pain. 60:1995;91-102.
2. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin-like growth factor 1. J. Biol. Chem. 272:1997;22330-22339.
3. 9-tetrahydrocannabinol in the rat and mouse. Psychopharmacol. Berlin. 25:1972;275-280.
4. Coderre T.J., Vaccarino A.L., Melzack R. Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection. Brain Res. 535:1990;155-158.
5. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
6. Devane W.A., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
7. Devane E.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
8. Dickenson A.H., Sullivan A.F. Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin. Pain. 30:1987;349-360.
9. Dubuisson D., Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 4:1977;161-174.
10. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656-7660.
11. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48:1995;443-450.
12. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R (+)-WIN 55, 212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 22:1997;157-160.
13. Hohmann A.G., Martin W.J., Tsou K., Walker J.M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55, 212-2. Life Sci. 56:1995;2111-2118.
14. Hohmann A.G., Tsou K., Walker J.M. Electrophysiological evidence for cannabinoid-modulation of spinal nociceptive processing. Soc. Neurosci. Abstr. 22:1996;512.
15. Landsman R.S., Burkey T.H., Consroe P., Roeske W.R., Yamamura H.I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334:1997;R1-R2.
16. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3825-3829.
17. Malmberg A.B., Yaksh T.L. Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N- and P-type channels inhibits formalin-induced nociception. J. Neurosci. 14:1994;4882-4890.
18. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16:1996;6601-6611.
19. Martin W.J., Lai N.K., Patrick S.L., Tsou K., Walker J.M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629:1993;300-304.
20. Martin W.J., Walker J.M., Fortin N.M., Salehani D., Prestwich G., Deutsch D.G. Evidence for a role of endogenous cannabinoids in nociceptive processing. Soc. Neurosci. Abstr. 21:1995;651.
21. McCarson K.E., Goldstein B.D. Time course of the alteration in dorsal horn substance P levels following formalin: blockade by naloxone. Pain. 41:1990;95-100.
22. 9-tetrahydrocannabinol as measured with the formalin test. Eur. J. Pharmacol. 61:1980;313-315.
23. Petitet F., Jeantaud B., Capet M., Doble A. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study. Biochem. Pharmacol. 54:1997;1267-1270.
24. Richardson J.D., Aanonsen L., Hargreaves K.M. SR141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:1997;R3-R4.
25. Richardson J.D., Aanonsen L.M., Hargreaves K.M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18:1998;451-457.
26. Rinaldi-Carmona M., Barth F., Héaulme M., Alonso R., Shire D., Congy C., Soubrié P., Brelière J., Le Fur G. Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56:1995;1941-1947.
27. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelière J., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. Fed. Eur. Biochem. Soc. 350:1994;240-244.
28. 3H ]-SR141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain Life Sci. 58:1996;1239-1247.
29. 9-tetrahydrocannabinol (THC). J. Pharmacol. Exp. Ther. 186:1973;646-655.
30. Terranova J.P., Storme J.J., Lafon N., Pério A., Rinaldi-Carmona M., Le Fur G., Soubrié P. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR141716. Psychopharmacology. 126:1996;165-172.
31. Tsou K., Lowitz K., Hohmann A.G., Martin W.J., Hathaway C.B., Bereiter D.A., Walker J.M. Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 70:1996;791-798.
32. Vaccarino A.L., Marek P., Liebeskind J.C. Stress-induced analgesia prevents the development of the tonic, late phase of pain produced by subcutaneous formalin. Brain Res. 572:1992;250-252.
33. Woolf C.J., King A.E. Dynamic alterations in the cutaneous mechanoreceptive fields of dorsal horn neurons in the rat spinal cord. J. Neurosci. 10:1990;2717-2726.